Ensuring the highest eradication rates in H. pylori: the case of non-bismuth quadruple concomitant therapy.
Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Adrian G
AG
McNicholl
Department of Microbiology & Infection Control, VU University Medical Center, Fransche Brug 22, Roelofarendsveen, The Netherlands.
A Salvador
AS
Pena
Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. Electronic address: javier.p.gisbert@gmail.com.
Javier P
JP
Gisbert
D000900:Anti-Bacterial Agents; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections; D016480:Helicobacter pylori; D006801:Humans; D008795:Metronidazole
D000900:Anti-Bacterial Agents; D008795:Metronidazole
Concomitant; Helicobacter pylori; Non-bismuth quadruple; Resistance; Treatment